January 29, 2020
Intercept has completed patient enrollment in its Phase 3 study evaluating obeticholic acid for the treatment of cirrhosis due to...
January 14, 2020
Alexion announced that is plans to start a Phase 3 study of ULTOMIRIS (ravulizumab) in amyotrophic lateral sclerosis (ALS).
October 11, 2019
The company announced positive results from its MAP US Phase 3 Study and MAP US2 Open-Label Extension Study
August 22, 2019
Retrophin (NASDAQ:RTRX) has announced that the Phase 3 FORT study evaluating the safety and efficacy of fosmetpantotenate compared to a...
May 9, 2018
Foamix Pharmaceuticals (NASDAQ:FOMX) a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs...
April 29, 2018
Eleven Biotherapeutics, EyePoint Pharmaceuticals, Avid Bioservices, Cerecor and Celldex were last week's top gainers on the NASDAQ.
April 26, 2018
Kalytera Therapeutics, Inc. (TSXV:KALY, OTCQB:KALTF) (the "Company" or "Kalytera") today issued the following letter to shareholders from the Company’s President...